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 INTRODUCTION 
 By the end of 1970s, the World Health Organization (WHO) 
declared that  Plasmodium vivax had been eradicated in the 
Republic of Korea (ROK). 1 In 1993, one case of malaria 
reemerged near the demilitarized zone (DMZ) that sepa-
rates ROK (south) from the Democratic People’s Republic 
of Korea (north). 2 Since 1993, the number of malaria cases 
has increased exponentially, not only among soldiers but also 
among civilians living near the DMZ. 3, 4 Although malaria did 
initially increase exponentially, the increase has since been 
tempered by control measures. Since 1997, the number of 
soldiers who received chemoprophylaxis with hydroxychlo-
roquine (HCQ) and primaquine has continuously increased 
to over 200,000 in 2005. Nonetheless, the number of cases of 
malaria has increased again since 2005 in the ROK Army. 
Military antimalarial chemoprophylaxis has contributed, in 
part, to the decrease in the number of malaria cases among 
military personnel. However, long-term chemoprophylaxis 
may facilitate the development of chloroquine (CQ)-resistant 
strains of  P. vivax . 
 Although the mechanism of  P. vivax CQ resistance is 
unknown, it has been suggested that the mutation of  pvmdr1 
that is the orthologue of the  pfmdr1 of  P. falciparum is related 
to the CQ resistance. 5, 6 
 We investigated the breakthrough malaria infection and the 
therapeutic efficacy of CQ in  P. vivax in ROK. Additionally, 
the  pvmdr1 gene polymorphisms and their relevance to CQ 
resistance in  P. vivax were evaluated. 
 MATERIALS AND METHODS 
 Study subjects.  From June 1 to September 30, 2006, we 
investigated the malaria patients who were admitted to the 
three referral Armed Forces Hospitals, Byeokje, Yangju, and 
Ildong Hospitals, located in the Northern Kyunggi province 
near the DMZ. The patients were diagnosed when they had 
any febrile illness and  P. vivax in peripheral blood films. 
Blood samples were obtained from all patients who had given 
the informed consent. The protocol was approved by the 
Institutional Ethic Committee at the Armed Forces Medical 
Command (April 13, 2006). 
 Compliance of chemoprophylaxis.  The chemoprophylaxis 
with HCQ sulfate (400 mg, one time per week) was started 
on May 8, 2006, and it continued throughout the transmission 
season (May to September). Therefore, the chemoprophylaxis 
was provided throughout the study period. Fourteen-day 
prophylaxis with primaquine (15 mg base, one time per 
day) was started on the first day of the last week of CQ 
administration. 
 The status of chemoprophylaxis was determined by the 
military record, which was a malaria case report form submit-
ted by the military doctor after the interview with the patient. 
According to the status of chemoprophylaxis, the patients were 
classified as complete compliance when they took all doses 
before malaria infection, poor compliance when they did not 
take the dose more than one time before malaria infection, 
and no prophylaxis when they did not take the dose at all. 
 Monitoring of therapeutic efficacy.  All patients diagnosed 
with vivax malaria received standard treatment: 2 g HCQ 
sulfate (day 1 dose, 1,200 mg; day 2 dose, 400 mg; day 3 dose, 
400 mg) and 15 mg primaquine one time daily for 14 days. 
The patients were followed-up 28 days after the start of 
antimalarial treatment; the protocol used was a slightly modi-
fied version of that antimalarial drug resistance monitoring 
that was originally suggested by WHO ( Table 1 ). 7 
 Identification of  pvmdr1 polymorphism.  Parasite genomic 
DNA from all blood samples collected into ethylene-
diaminetetraacetic acid (EDTA) tubes was extracted with a 
QIAamp DNA blood kit (QIAGEN Inc., Valencia, CA) 
following the manufacturer’s instructions with minor modi-
fications: the incubation time with proteinase K was increased 
to 1 hour at 56°C to improve the yield of the extraction, and 
DNA was eluted from the column by use of 100 mL polymerase 
chain reaction (PCR)-grade H 2 O. Genomic DNA from 
 P. vivax was amplified in a total volume of 20 μL containing 
0.20 mmol/L 2’-deoxynucleoside 5’-triphosphate (dNTP), 
1 μmol/L each primer, 1 U Platinum Taq DNA Polymerase 
(Invitrogen), 1.5 mmol/L MgCl 2 , and 5 μL 10× PCR buffer. 
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The sequences of PCR primers were as follows:  pvmdr1 -F 
(5′-CACCTTGCCCTTCTTCGT-3′),  pvmdr1 -R (5′-TTCA
CCTTCTTGTTGCAAATAAC-3′),  pvmdr1 -S (5′-ATAGTCA
TGCCCCAGGATTG-3′), and  pvmdr1 -AS (5′-ACGTTTGG
TCTGGACAAGTATC-3′). PCR was performed under the 
following conditions: 37 cycles of denaturation at 94°C (5 min 
in the first cycle and 30 s in subsequent cycles), annealing for 
30 s at 55°C, extension for 30 s at 72°C, and a final primer 
extension for 7 min. PCR products were sequenced using 
the ABI Prism 3100 Genetic Analyzer (Applied Biosystems, 
Foster City, CA). The sequences were compared with the 
 pvmdr1 (GenBank accession number AY618622) of Sal-1, 
a CQ-susceptible strain from Salvador, 8 using a basic local 
alignment search tool (BLAST) search of the National Center 
for Biotechnology Information databases ( http://blast.ncbi
.nlm.nih.gov/Blast.cgi ). 
 RESULTS 
 During the study period, a total of 149 patients were diag-
nosed as  P. vivax malaria in the study hospitals. The status of 
chemoprophylaxis was determined for 102 patients whose mil-
itary records were available, and the therapeutic efficacy was 
monitored for 28 days after standard HCQ treatment in the 
85 patients who had given the informed consent ( Figure 1 ); 
66 (64.7%) patients were classified as complete compliance, 
11 (10.8%) patients had poor compliance, and 25 (24.5%) 
patients had no prophylaxis ( Table 2 ). All peripheral blood 
smears needed for monitoring had been done in all 85 patients, 
and all enrolled patients cleared their parasites within 3 days. 
 The PCR was performed from the blood samples that were 
obtained from the 85 patients who enrolled in therapeutic 
efficacy monitoring. After PCR, the 78 isolates were obtained 
successfully from the 85 patients. After sequencing the PCR 
products, the single-nucleotide polymorphisms of  pvmdr1 
were analyzed, and the phenylalanine (F) of codon 1076 in 
 pvmdr1 was found to be substituted by leucine (L) in all iso-
lates, including 63 patients with complete compliance. The 
other mutations, including Y976F, were not found. 
 DISCUSSION 
 The mass chemoprophylaxis for the soldiers based in the 
risk area reduced the number of malaria cases, but long-term 
chemoprophylaxis could facilitate the development of drug 
resistance/tolerance or prophylaxis failure. 9, 10 In this study, 
66 patients were defined as complete compliance by the mili-
tary record. The drug level in whole blood of the patients with 
chemoprophylaxis was not measured at the malaria infection; 
it is highly likely that the drug concentration in patients with 
complete compliance could be higher than 100 ng/mL, because 
it is usually known that the drug concentration is maintained 
higher than 100 ng/mL by the long-term CQ prophylaxis given 
one time per week. 11  P. vivax may be classified as biologically 
resistant if malaria infection that persists in the CQ level in 
whole blood is greater than 100 ng/mL, and it should com-
pletely cure blood-stage CQ-sensitive  P. vivax . 12 However, Lee 
and others 13 showed that the HCQ and its metabolite could not 
be found in the blood of 46 of 74 soldiers who had taken HCQ 
chemoprophylaxis weekly, although the blood concentration 
of the HCQ and its metabolites was above 100 ng/mL in eight 
patients. Therefore, it is not truly breakthrough malaria in the 
66 patients regarded as complete compliance group. 
 The  pfmdr1 gene of  P. falciparum is classified as the adenos-
ine 5′-triphosphate (ATP) binding cassette (ABC) transporter, 
and it has been known to relate with the resistance against 
CQ, artemisinin, quinine, mefloquine, and halofantrine. 14 The 
 pvmdr1 gene of  P. vivax is the orthologue of the  pfmdr1 of 
 P. falciparum , and there is controversy regarding whether the 
 pvmdr1 gene relates with the CQ resistance. 5, 6, 15, 16 A recent study 
showed that the amplification of  pvmdr1 and single-nucleotide 
polymorphisms was correlated with susceptibility of  P. vivax to 
multiple antimalarial drugs and that the  pvmdr1 Y976F allele 
had reduced susceptibility to CQ. 17 In this study, the F → L 
change at codon 1076 of the  pvmdr1 , which was caused by a 
single mutation (TTT → CTT), was observed in all 78 isolates. 
Therefore, this ubiquitous presence of the F1076L mutation of 
the  pvmdr1 might be correlated with geographical characteris-
tics in Korean vivax malaria rather than drug resistance. 
 In this study, no treatment failure was observed after the 
standard treatment of CQ/primaquine in 85 patients for the 
28 days of monitoring. Considering the blood schizonticidal 
effect of primaqine, 18 it could not be determined that there 
was absolutely no CQ treatment failure, but it could be deter-
mined that there was no standard treatment failure. 
 Table 1 
 Modified protocol of the WHO for antimalarial drug monitoring 
Day 0 1 2 3 7 14 21 28
Clinical examination and temperature × × × × × × × ×
Treatment with CQ × × ×
Parasitemia × × × × × ×
Molecular markers ×
 Figure 1.  Study enrollment flowchart. 
 Table 2 
 Baseline characteristics of patients with vivax malaria 
Characteristics * ( N = 102) Measurement
Mean age (in years) ± standard deviation 
(range) 22.5 ± 3.3 (17–36)
Residency
 Northwestern, Kyeonggi (Byeokje) 44 (43.1%)
 Mid-north, Kyeonggi (Yangju) 36 (35.3%)
 Northeastern, Kyeonggi (Ildong) 23 (22.6%)
Compliance
 Complete 66 (64.7%)
 Poor 11 (10.8%)
 No 25 (24.5%)
Median parasitemia count per microliter 
(IQR † ) 2,250 (490–8050) ‡ 
 * All patients were male. 
 †  IQR = interquartile range. 
 ‡  Complete compliance group (2,057/1 μL) vs. poor and no prophylaxis groups (4,558/1 μL). 
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 In this study, there were limitations. For example, the blood 
levels of CQ and its metabolites, desethylchloroquine and des-
ethylhydroxychloroquine, were not measured after the vivax 
malaria was developed. In conclusion, there was no treatment 
failure of HCQ and primaquine in Korea, and there was no 
evidence that that the F1076L mutation of  pvmdr1 could con-
tribute to HCQ resistance in  P. vivax . 
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